Group II metabotropic glutamate receptors are a common target of N-anisoyl-GABA and 1S,3R-ACPD in enhancing ACh release in the prefrontal cortex of freely moving SHRSP

Neuropharmacology

Volumn 39, Issue 5, 2000, Pages 866-872

  Shirane, Masatoshi ^a   Nakamura, Kazuo ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

Acetylcholine; Aniracetam; Group II metabotropic glutamate receptor; Microdialysis; N anisoyl GABA; Stroke prone spontaneously hypertensive rats

Indexed keywords

6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; ACETYLCHOLINE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANIRACETAM; DRUG METABOLITE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; METABOTROPIC RECEPTOR; NOOTROPIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; MALE; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE;

ACETYLCHOLINE; ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; AMINO ACIDS, DICARBOXYLIC; ANIMALS; ANISOLES; BENZOATES; CYCLOLEUCINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; GLYCINE; HIPPOCAMPUS; INDANS; MALE; MICRODIALYSIS; PERFUSION; PREFRONTAL CORTEX; QUINOXALINES; RATS; RATS, INBRED SHR; RECEPTORS, AMPA; RECEPTORS, METABOTROPIC GLUTAMATE; THALAMIC NUCLEI; WAKEFULNESS;

EID: 0033976803     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00271-3     Document Type: Article

References (46)

1. Altar C.A. Neurotrophins and depression. Trends in Pharmacological Science. 20:1999;59-61.
2. Altar C.A., Fritsche M., Lindsay R.M. Cell body infusions of brain-derived neurotrophic factor increase forebrain dopamine release and serotonin metabolism determined with in vivo microdialysis. Advances in Pharmacology. 42:1998;915-921.
3. Bessho Y., Nakanishi S., Nawa H. Glutamate receptor agonists enhance the expression of BDNF mRNA in cultured cerebellar granule cells. Brain Research and Molecular Brain Research. 18:1993;201-208.
4. Bond A., O'Neill M.J., Hicks C.A., Monn J.A., Lodge D. Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia. NeuroReport. 9:1998;1191-1193.
5. Camon L., Vives P., de Vera N., Martinez E. Seizures and neuronal damages induced in the rat by activation of group I metabotropic glutamate receptors with their selective agonist 3,5-dihydroxyphenylglycine. Journal of Neuroscience Research. 51:1998;339-348.
6. Chen J., Delaney K.H., Kwiecien J.M., Lee R.M.K.W. The effects of dietary sodium on hypertension and stroke development in female stroke-prone spontaneously hypertensive rats. Experimental Molecular Pathology. 64:1997;173-183.
7. Conn P.J., Pin J.-P. Pharmacology and functions of metabotropic glutamate receptors. Annual Reviews of Pharmacology and Toxicology. 37:1997;205-237.
8. Giovannini M.G., Rakovska A., Della Corta L., Bianchi L., Pepeu G. Activation of non-NMDA receptors stimulates acetylcholine and GABA release from dorsal hippocampus: a microdialysis study in the rat. Neuroscience Letters. 243:1998;152-156.
9. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., Kallman M.J. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. Journal of Pharmacology and Experimental Therapeutics. 284:1998;651-660.
10. Honma S., Takei A., Fukuzawa T., Hamada K., Hamada T. Treatment of Parkinson's disease with aniracetam. Aging Diseases. 8:1995;96-99.
11. Katsunuma H., Shimizu T., Ogawa K., Kubo H., Ishida H., Yoshihama A. Treatment of insomnia by concomitant therapy with zopiclone and aniracetam in patients with cerebral infarction, cerebroatrophy, Alzheimer's disease and Parkinson's disease. Psychiatry and Clinical Neuroscience. 52:1998;198-200.
12. Keinänen K., Wisden W., Sommer B., Werner P., Herb A., Verdoorn T.A., Sakmann B., Seeburg P.H. A family of AMPA-selective glutamate receptors. Science. 249:1990;556-560.
13. Kendrick K.M., Guevara-Guzman R., de la Riva C., Christensen J., Østergaard K., Emson P.C. NMDA and kinate-evoked release of nitric oxide and classical transmitters in the rat striatum: in vivo evidence that nitric oxide may play a neuroprotective role. European Journal of Neuroscience. 8:1996;2619-2634.
14. Kimura, M., Okano, Y., Inoué, S., 2000. Effects of aniracetam on impaired sleep patterns in stroke-prone spontaneously hypertensive rats. Psychiatry and Clinical Neuroscience, 54, in press.
15. Knöpfel T., Kuhn R., Allgeier H. Metabotropic glutamate receptors: novel targets for drug development. Journal of Medicinal Chemistry. 38:1995;1417-1426.
16. Kondoh Y., Asanuma M., Kabuto H., Iwata E., Kondoh F., Miyazaki I., Ogawa N. Aniracetam ameliorates impaired pre- and post-synaptic cholinergic indices in gerbil hippocampus induced by transient forebrain ischemia. Journal of Brain Science. 23:1997;250-260.
17. Konieczny J., Ossowska K., Wolfarth S., Pilc A. LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn Schmiedeberg's Archives of Pharmacology. 358:1998;500-502.
18. Lu Y., Wehner J.M. Enhancement of contextual fear-conditioning by putative (±)-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor modulators and N-methyl-D-aspartate (NMDA) receptor antagonists in DBA/2J mice. Brain Research. 768:1997;197-207.
19. Masana Y., Wanaka A., Kato H., Asai T., Tohyama M. Localization of trkB mRNA in postnatal brain development. Journal of Neuroscience Research. 35:1993;468-479.
20. Martin J.R., Haefely W.E. Pharmacology of aniracetam: a novel pyrrolidinone derivative with cognitive enhancing activity. Drug Investigations. 5(Suppl. 1):1993;4-49.
21. Mesulam M.-M., Geula C., Bothwell M.A., Hersh L.B. Human reticular formation: cholinergic neurons of the pedunculopontine and laterodorsal tegmental nuclei and some cytochemical comparisons to forebrain cholinergic neurons. Journal of Comparative Neurology. 283:1989;611-633.
22. Murray K.D., Wood P.L., Rosasco C., Isackson P.J. A metabotropic glutamate receptor agonist regulates neurotrophin messenger RNA in rat forebrain. Neuroscience. 70:1996;617-630.
23. Nagasaka T., Togashi S., Amano A., Nitta K., Shindo K., Shiozawa Z. Aniracetam for treatment of patients with progressive supranuclear palsy. European Neurology. 37:1997;195-198.
24. Nakamura K., Kurasawa M., Tanaka Y. Scopolamine model of delirium in rats and reversal of the performance impairment by aniracetam. Drug Development Research. 43:1998;85-97.
25. Nakamura K., Kurasawa M., Tanaka Y. Apomorphine-induced hypoattention in rats and reversal of the choice performance impairment by aniracetam. European Journal of Pharmacology. 342:1998;127-138.
26. Nakamura K., Shirane M. Activation of the reticulothalamic cholinergic pathway by the major metabolites of aniracetam. European Journal of Pharmacology. 380:1999;81-89.
27. Nicoletti F., Bruno V., Copani G., Casabona G., Knöpfel T. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends in Neuroscience. 19:1996;267-271.
28. Ogiso T., Iwaki M., Tanino T., Ikeda K., Paku T., Horibe Y., Suzuki H. Pharmacokinetics of aniracetam and its metabolites in rats. Journal of Pharmaceutical Science. 87:1998;594-598.
29. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience. 53:1993;1009-1018.
30. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. Journal of Comparative Neurology. 335:1993;252-266.
31. Otomo E., Hirai S., Terashi A., Hasegawa K., Tazaki Y., Araki G., Itoh E., Nishimura T., Furukawa T. Clinical usefulness of aniracetam for psychiatric symptoms in patients with cerebrovascular disorders: Double-blind trial placebo. Journal of Clinical Experimental Medicine. 156:1991;143-187.
32. Parain K., Murer M.G., Yan Q., Faucheux B., Agid Y., Hirsch E., Raisman-Vozari R. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. NeuroReport. 10:1999;557-561.
33. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd ed. 1986;Academic Press, New York.
34. Phillips H.S., Hains J.M., Armanini M., Laramee G.R., Johnson S.A., Winslow J.W. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron. 7:1991;695-702.
35. Pintor A., Tiburzi F., Pezzola A., Volpe M.T. Metabotropic glutamate receptor agonist (1S,3R-ACPD) increased frontal cortex dopamine release in aged but not in young rats. European Journal of Pharmacology. 359:1998;139-142.
36. Pizzi M., Fallacara C., Arrighi V., Memo M., Spano P.-F. Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells. Journal of Neurochemistry. 61:1993;683-689.
37. Pizzi M., Consolandi O., Memo M., Spano P.-F. Activation of multiple metabotropic glutamate receptor subtypes prevents NMDA-induced excitotoxicity in rat hippocampal slices. European Journal of Neuroscience. 8:1996;1516-1521.
38. Roncari G. Human pharmacokinetics of aniracetam. Drug Investigations. 5(Suppl. 1):1993;68-72.
39. Sacaan A.I., Bymaster F.P., Schoepp D.D. Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine. Journal of Neurochemistry. 59:1992;245-251.
40. Sala R., Viegi A., Rossi F.M., Pizzorusso T., Bonanno G., Raiteri M., Maffei L. Nerve growth factor and brain-derived neurotrophic factor increase neurotransmitter release in the rat visual cortex. European Journal of Neuroscience. 10:1998;2185-2191.
41. Schoepp D.D. Novel functions for subtypes of metabotropic glutamate receptors. Neurochemistry International. 24:1994;439-449.
42. Senin U., Pernetti L., Cucinotta D., Criscuolo D., Longo A., Marini G. Clinical experience with aniracetam in the treatment of senile dementia of Alzheimer's type and related disorders. Drug Investigations. 5(Suppl. 1):1993;96-105.
43. Shigemoto R., Nakanishi S., Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: an in situ hybridization study in adult and developing rat. Journal of Comparative Neurology. 332:1992;121-135.
44. Togashi H., Kimura S., Matsumoto M., Yoshioka M., Minami M., Saito H. Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke. 27:1996;520-526.
45. Togashi H., Matsumoto M., Yoshioka M., Hirokami M., Minami M., Saito H. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neuroscience Letters. 166:1994;117-120.
46. Wultz B., Sagvolden T., Moser E.I., Moser M.-B. The spontaneously hypertensive rat as an animal model of attention-deficit hyperactivity disorder: effects of methylphenidate on exploratory behavior. Behaviour and Neural Biology. 53:1990;88-102.